Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China.
Wei LiLi WanPublished in: Expert review of pharmacoeconomics & outcomes research (2024)
ORIENT-16, www.clinicaltrials.gov, identifier is NCT03745170.